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discussed in the article and noted by the corre-
spondents, this finding was contrasted to the ab-
sence of any imbalance in cardiovascular events 
in the larger placebo-controlled FRAME. These 
contrasting results have raised questions about 
the possible cardioprotective effect of alendro-
nate or particular characteristics of the patients 
in our trial that may have made them more sus-
ceptible to cardiovascular events. We agree with 
Song and Lee that further investigation of this 
finding is warranted. We agree that osteoporosis 
treatment is generally intended to be long-term, 
but because of its time-limited bone-forming ef-
fect, romosozumab has been studied as a 1-year 
course of treatment and is not intended for con-
tinuous long-term use. As is good standard prac-
tice with all drugs, the benefits and potential 
risks of the product will have to be carefully 
assessed in order to make treatment decisions 
for individual patients.
Both the Prince and Hofbauer groups high-
light the role of DKK1 on the vasculature and 
suggest further investigations to better under-
stand the cardiovascular risk status of the pa-
tients in our trial. We have considered examin-
ing available spine images for aortic calcification 
in our trial. Although there is evidence of an 
association between aortic calcification and the 
risk of cardiac events in cross-sectional studies,1 
changes in aortic calcification during a time-
limited pharmacologic intervention have not been 
shown to be predictive of a change in the risk of 
cardiovascular events.2 As suggested by Hofbauer’s 
group, we measured DKK1 in response to romo-
sozumab in ovariectomized cynomolgus mon-
keys3 but found no significant change, which 
appears to be consistent with earlier findings in 
a rat model of progressive renal osteodystrophy 
in which there also was no significant change 
in DKK1 levels in response to sclerostin anti-
body treatment.4 Thus, there is limited biologic 
plausibility to pursue this association further 
in humans.
Kenneth G. Saag, M.D.
University of Alabama 
Birmingham, AL 
ksaag@ uab . edu
Jeffrey Petersen, M.D. 
Andreas Grauer, M.D.
Amgen 
Thousand Oaks, CA
Since publication of their article, the authors report no fur-
ther potential conflict of interest.
1. Wilson PW, Kauppila LI, O’Donnell CJ, et al. Abdominal aor-
tic calcific deposits are an important predictor of vascular mor-
bidity and mortality. Circulation 2001; 103: 1529-34.
2. Samelson EJ, Miller PD, Christiansen C, et al. RANKL inhibi-
tion with denosumab does not influence 3-year progression of 
aortic calcification or incidence of adverse cardiovascular events 
in postmenopausal women with osteoporosis and high cardio-
vascular risk. J Bone Miner Res 2014; 29: 450-7.
3. Ominsky MS, Boyd SK, Varela A, et al. Romosozumab im-
proves bone mass and strength while maintaining bone quality 
in ovariectomized cynomolgus monkeys. J Bone Miner Res 2017; 
32: 788-801.
4. Moe SM, Chen NX, Newman CL, et al. Anti-sclerostin anti-
body treatment in a rat model of progressive renal osteodystro-
phy. J Bone Miner Res 2015; 30: 499-509.
DOI: 10.1056/NEJMc1714810
Canakinumab for Atherosclerotic Disease
To the Editor: Ridker et al. (Sept. 21 issue)1 
found in the Canakinumab Antiinflammatory 
Thrombosis Outcome Study (CANTOS) that re-
duced inflammation was associated with reduced 
cardiovascular risk. Unfortunately, the opportu-
nity to identify the precise point of action of 
canakinumab has not been exploited in this trial.
18F-fluorodeoxyglucose (FDG) positron emis-
sion tomography (PET) is a validated molecular 
imaging technique that is widely used to non-
invasively quantify plaque inflammation during 
treatment with therapeutic agents targeted at 
reducing atherosclerotic inflammation.2 Inflam-
matory activity that is detected by PET positively 
correlates with intraplaque macrophage infiltra-
tion.3 This trial could have used PET to verify 
that the observed reduction in the surrogate 
marker high-sensitivity C-reactive protein indeed 
correlates with reductions in plaque inflamma-
tion or that this effect can be primarily attrib-
uted to modification of extraarterial immunity,2 
as described for canakinumab.4 PET could have 
also been used to elucidate the systemic effects 
of targeting the interleukin-1β innate immunity 
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pathway — for example, by assessment of the 
metabolic state of lymphoid organs and hemato-
poietic tissue.5 Finally, PET could have been used 
to identify the patients with marked plaque in-
flammation who will benefit most from this 
expensive therapeutic approach.
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To the Editor: CANTOS showed that interleukin-
1β inhibition confers a significantly reduced risk 
of recurrent myocardial infarction. This finding 
implies that immune-mediated inflammatory 
diseases, including psoriasis, rheumatoid arthri-
tis, and inflammatory bowel disease, are indeed 
independent risk factors for incident cardiovas-
cular disease. Beneficial effects of antiinflam-
matory treatment on the progression of cardio-
vascular disease and on cardiovascular events 
have previously been shown among patients 
with psoriasis in registry-based and cardiovas-
cular imaging studies.1,2 For clinicians treating 
inflammation-driven diseases, CANTOS provides 
arguments for tight disease control through early 
and aggressive dampening of systemic inflam-
mation to prevent premature development of car-
diovascular disease.3 Although the upstream in-
hibition of the proinflammatory cascade with 
canakinumab, in combination with potential 
safety aspects of interleukin-1 inhibition, could 
make this particular cytokine target problematic 
for primary and secondary prevention of car-
diovascular disease, the early indications from 
CANTOS may lead to a radical shift in the man-
agement of immunoinflammatory diseases across 
a wide range of medical specialties.
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To the Editor: CANTOS showed that inhibition 
of interleukin-1β reduced high-sensitivity C-reac-
tive protein levels and improved clinical out-
comes in patients with stable coronary artery 
disease, indicating that high-sensitivity C-reac-
tive protein is a biomarker of cardiovascular risk 
and that interleukin-1β is a driver of vascular in-
flammation. The hazard ratios for the primary 
end point were 0.93 in the group that received the 
50-mg dose of canakinumab, 0.85 in the 150-mg 
group, and 0.86 in the 300-mg group, but were 
0.90, 0.83, and 0.79, respectively, among adherent 
patients.
The MRC-ILA Heart Study1 showed effective 
suppression of high-sensitivity C-reactive protein 
in non–ST-segment elevation acute coronary 
syndromes after 14 days of treatment with an 
interleukin-1 receptor antagonist. However, after 
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discontinuation of the agent, these patients had 
a higher level of high-sensitivity C-reactive pro-
tein at day 30 than patients who had received 
placebo and a higher rate of major adverse car-
diac events at 1 year. Unpublished data from the 
MRC-ILA Heart Study show that among patients 
who received the interleukin-1 receptor antago-
nist, those who had major adverse cardiac events 
had higher levels of high-sensitivity C-reactive 
protein at day 1 (baseline), day 14 (end of treat-
ment), and day 30 than those who did not have 
major adverse cardiac events (Fig. 1). Clinical 
and biologic data from nonadherent patients in 
CANTOS would be informative when physicians 
consider withdrawal from therapies that target 
interleukin-1.
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To the Editor: In CANTOS, blocking interleukin-
1β reduced the incidence of atherothrombosis 
and nonfatal stroke, and an additional analysis 
Figure 1. High-Sensitivity C-Reactive Protein (CRP) 
 Levels in Patients with Non–ST-Segment Elevation 
Acute Coronary Syndromes.
Panel A shows the geometric mean level of high-sensi-
tivity CRP according to group at days 1 through 7, 14, 
and 30. Patients who received an interleukin-1 receptor 
antagonist (IL-1RA) for 14 days had lower levels of high-
sensitivity CRP at day 14 than those who received pla-
cebo. However, at day 30 (16 days after the intervention 
period), those who had received IL-1RA had higher levels 
of high-sensitivity CRP than those who had received 
placebo. Among patients who received IL-1RA, those 
who had major adverse cardiac events (MACE) had 
higher levels of high-sensitivity CRP at days 1, 14, and 
30 than those who did not have MACE. Panel B shows 
the high-sensitivity CRP level in individual patients 
 (circles) at days 1, 14, and 30. In the box plots, the hori-
zontal line inside the box indicates the median, the top 
and bottom of the box indicate the interquartile range, 
and the I bars indicate the 5th and 95th percentiles.
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showed that patients who received the 300-mg 
dose of canakinumab had a total cancer mortal-
ity that was lower by 51% than those who re-
ceived placebo and a lung-cancer mortality that 
was lower by 77%.1 The incidence of fatal infec-
tion was nearly twice as high in the pooled 
canakinumab groups as in the placebo group, a 
finding similar to that observed with the inter-
leukin-1 receptor antagonist anakinra.2 The ac-
companying editorial by Harrington3 discussed 
the safety risk of interleukin-1β blockade.
Interleukin-1β is driven by multiple inflam-
masomes. As an alternative to inhibition of 
interleukin-1β, precise inhibition of a single 
inflammasome, NLRP3, is likely to be safer. 
NLRP3 is implicated in diseases of aging, such as 
atherosclerosis and neurodegenerative disorders. 
Selective NLRP3 inhibition will leave other in-
flammasomes to respond to infection. In addi-
tion, at the onset of severe infection, an orally 
available small molecule could be withdrawn, 
whereas canakinumab cannot. NLRP3 activation 
also drives interleukin-18, the clinical targeting 
of which is also safe.4
CANTOS has advanced our understanding of 
the clinical relevance of interleukin-1β and the 
NLRP3 inflammasome. This trial will drive the 
development and commercialization of an entirely 
new class of drugs.
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To the Editor: The trial by Ridker et al. exam-
ined canakinumab in a cohort of patients with 
established coronary artery disease. Although the 
reduction in cardiovascular events was signifi-
cant (hazard ratio, 0.85), the disconcerting re-
sults included an increased risk of fatal infection 
and no mortality benefit. In addition, the drug is 
expensive ($200,000 per year). The accompanying 
editorial calls for alternative, more cost-effective 
antiinflammatory agents without the associated 
risk of fatal infection.
In a prospective, randomized, secondary-pre-
vention trial, colchicine, an ancient1 but inex-
pensive antiinflammatory drug with pleiotropic 
effects including the targeting of neutrophils, 
resulted in a reduced rate of recurrent cardiovas-
cular events (hazard ratio, 0.29) without an in-
crease in fatal infection.2 In light of this finding, 
it is surprising that this agent was not acknowl-
edged by the authors, because at face value, it 
seems to fulfill the requirements suggested in 
the editorial. Although studies of colchicine thus 
far have been predominantly investigator-initiated 
and smaller in size, it is to be hoped that ongo-
ing research will confirm the initial promising 
results with this drug.
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The editorialist replies: O’Neill and Cooper 
as well as Nerlekar and Harper provide commen-
tary on the recent report on CANTOS and the 
accompanying editorial. Both letters point to 
the observation of an increased risk of serious 
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or fatal infections in the trial and note that per-
haps alternative antiinflammatory agents might 
provide the clinical cardiovascular benefit ob-
served with canakinumab but with a better safety 
profile. O’Neill and Cooper present the hypoth-
esis that a more specific inhibitor of interleukin-
1β, perhaps through inhibition of NLRP3, might 
prove safer than canakinumab. Certainly, this is 
a reasonable concept to consider for future inves-
tigation.
Nerlekar and Harper express surprise that 
colchicine was not mentioned in my editorial as 
an antiinflammatory agent worthy of further 
investigation, given the findings from a small 
study (involving 532 patients) that suggested a 
possible clinical cardiovascular benefit from 
colchicine among patients with stable coronary 
artery disease.1 This trial also showed that 11% 
of the patients who received colchicine discon-
tinued the treatment in the first 30 days owing 
to gastrointestinal intolerance. A better under-
standing of the balance between risks and bene-
fits requires a much larger clinical trial, powered 
appropriately for the clinical cardiovascular out-
comes and with sufficient monitoring for an 
assessment of safety.
A recent Cochrane meta-analysis on colchicine 
in heart disease concluded that there was uncer-
tainty regarding its risks and benefits in patients 
with heart disease but that it was worthy of fur-
ther investigation.2 This seems to be a reason-
able conclusion. My editorial noted that “CANTOS 
has helped move the inflammatory hypothesis 
of coronary artery disease forward scientifically.” 
Further investigation with alternative antiinflam-
matory agents that conserve or even accentuate 
the cardiovascular benefits of canakinumab 
while improving on its safety and cost charac-
teristics would be welcomed.
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Oxygen Therapy in Suspected Acute Myocardial Infarction
To the Editor: Hofmann et al. (Sept. 28 issue)1 
found that oxygen supplementation in patients 
with suspected myocardial infarction who did 
not have hypoxemia at baseline did not affect 
1-year mortality or the incidence of rehospitaliza-
tion after 30 days. The trial outcome measures 
did not include any related to neurologic func-
tion or quality of life, despite the fact that cogni-
tive deficits and functional disability often occur 
after myocardial infarction.2
It is unknown whether myocardial infarction, 
particularly in patients who have chronic hyper-
tension or who are elderly, compromises cerebral 
perfusion at values that would be considered 
normotensive in most patients, because monitor-
ing of brain-tissue oxygenation has not been 
performed in patients with normal oxygen levels 
during myocardial infarction. Cerebral hypoxia can 
occur in the absence of peripheral hypoxemia in 
particular clinical scenarios.3,4 The DETO2X-AMI 
(Determination of the Role of Oxygen in Sus-
pected Acute Myocardial Infarction) trial was 
conducted predominantly in Swedes, whose vul-
nerability to cerebral hypoperfusion may differ 
from that of other ethnic groups, potentially 
limiting generalizability. Post hoc analysis of 
neurologic function in DETO2X-AMI participants, 
or a sufficiently powered subgroup of them, 
could be performed to determine whether oxy-
gen supplementation decreases the risk of neu-
rologic compromise in myocardial infarction.
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